Prevention of Neutropenia-Related Events in Elderly Patients with Hematological Cancer

• Lyman GH , KudererNM, BalducciL. Cancer care in the elderly: cost and quality-of-life considerations. Cancer Control5, 347–354(1998).
   PubMedGoogle Scholar
• Sant M , AllemaniC, TereanuCet al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the Haemacare project. Blood 116, 3724–3734(2010).
   PubMed Web of Science ®Google Scholar
• Menzin J , LangK, EarleKet al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med. 162, 1597 (2002).
   PubMed Web of Science ®Google Scholar
• Extermann M . Geriatric oncology: an overview of progresses and challenges. Cancer Res. Treat.42, 61–68(2010).
   PubMed Web of Science ®Google Scholar
• Balducci L , ExtermannM. Cancer and aging. An evolving panorama. Hematol. Oncol. Clin. North Am.14, 1–15(2000).
   PubMed Web of Science ®Google Scholar
• Gillison TL , ChattaGS. Cancer chemotherapy in the elderly patient. Oncology24, 76–92(2010).
   PubMed Web of Science ®Google Scholar
• Ferra C , MarcosP, MisisMet al. Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. Int. J. Hematol. 85, 195–202(2007).
   PubMed Web of Science ®Google Scholar
• Norgaard M , LarssonH, PedersenGet al. Short-term mortality of bacteraemia in elderly patients with haematological malignancies. Br. J. Haematol. 32, 25–31(2005).
   Google Scholar
• Baker SD , GrochowLB. Pharmacology of cancer chemotherapy in the older person. Clin. Geriatr. Med.13, 169–183(1997).
   PubMed Web of Science ®Google Scholar
• Baraldi-Junkins CA , BeckAC, RothsteinG. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol. Oncol. Clin. North Am.14, 45–61(2000).
   PubMed Web of Science ®Google Scholar
• Rothstein G . Disordered hematopoiesis and myelodysplasia in the elderly. J. Am. Geriatr. Soc.51(3 Suppl.), S22–S26 (2003).
   PubMed Web of Science ®Google Scholar
• Sawhney R , SehlM, NaeimA. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J.11, 449–460(2005).
   PubMed Web of Science ®Google Scholar
• Lyman GH , LymanCH, AgboolaO. Risk models for predicting chemotherapy-induced neutropenia. Oncologist10, 427–437(2005).
   PubMed Web of Science ®Google Scholar
• Lyman GH , KudererNM, BalducciL. Cost–benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr. Opin. Hematol.9, 207–214(2002).
   PubMed Web of Science ®Google Scholar
• Klastersky J , PaesmansM, RubensteinEBet al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J. Clin. Oncol. 18, 3038–3051(2000).
   PubMed Web of Science ®Google Scholar
• Lalami Y , PaesmansM, MuanzaFet al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors?. A retrospective analysis. Ann. Oncol. 17, 507–514(2006).
   PubMed Web of Science ®Google Scholar
• Gerlier L , LamotteM, AwadaAet al. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin‘s lymphoma. BMC Cancer 10, 642 (2010).
   PubMed Web of Science ®Google Scholar
• Balducci L , HardyCL, LymanGH. Hematopoietic growth factors in the older cancer patient. Curr. Opin. Hematol.8, 170–187(2001).
   PubMed Web of Science ®Google Scholar
• Balducci L , LymanGH, OzerH. Patients aged ≥70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J. Clin. Oncol.19, 1583–1585(2001).
   PubMed Web of Science ®Google Scholar
• Freifeld A , BowEJ, SepkowitzKAet al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52, e56–e93 (2011).
   PubMed Web of Science ®Google Scholar
• Repetto L , BiganzoliL, KoehneCHet al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur. J. Cancer 39, 2264–2272(2003).
   PubMed Web of Science ®Google Scholar
• Balducci L , Al-HalawaniH, CharuVet al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12, 1416–1424(2007).
   PubMed Web of Science ®Google Scholar
• Aapro MS , CameronDA, PettengellRet al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer 42, 2433–2453(2006).
   PubMed Web of Science ®Google Scholar
• Caimi PF , BarrP, BergerNAet al. Non Hodgkin‘s lymphoma in the elderly. Drugs Aging 27, 211–238(2010).
   PubMed Web of Science ®Google Scholar
• Sonneveld P , de Ridder M, Van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin‘s lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol.13, 2530–2539(1995).
   PubMed Web of Science ®Google Scholar
• Tirelli U , ErranteD, Van Glabbeke M et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin‘s lymphoma. Results of a randomized study of the European Organization for Research and Treatment Cancer Lymphoma Cooperative Study Group. J. Clin. Oncol.16, 27–34(1998).
   PubMed Web of Science ®Google Scholar
• Gomez H , HidalgoM, CasanovaLet al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin‘s lymphoma: results of a multivariate analysis. J. Clin. Oncol. 16, 2065–2069(1998).
   PubMed Web of Science ®Google Scholar
• Tucci A , FerrariS, BottelliCet al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115, 4547–4553(2009).
   PubMed Web of Science ®Google Scholar
• Ruan J , MartinP, ColemanMet al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 116, 2655–2664(2010).
   PubMed Web of Science ®Google Scholar
• Kurzwelly D , GlasM, RothPet al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J. Neurooncol. 97, 389–392(2010).
   PubMed Web of Science ®Google Scholar
• Ösby E , HagbergH, TeerenhoviLet al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 101, 3840–3848(2003).
   PubMed Web of Science ®Google Scholar
• Wingard JR , ElmongyM. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit. Rev. Oncol. Hematol.72, 144–154(2009).
   PubMed Web of Science ®Google Scholar
• Klastersky J , AwadaA, PaesmansMet al. Febrile neutropenia: a critical review of the initial management. Crit. Rev. Oncol. Hematol. 78, 185–194(2011).
   PubMed Web of Science ®Google Scholar
• Coiffier B , LepageE, BrièreJet al. CHOP-chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242(2002).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M , TrümperL, KloessMet al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104, 634–641(2004).
   PubMed Web of Science ®Google Scholar
• Klastersky J , AwadaA. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice?. Crit. Rev. Hematol. Oncol.78, 17–23(2011).
   PubMed Web of Science ®Google Scholar
• Wolf M , BentleyM, MarltonPet al. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin‘s lymphoma. Leuk. Lymphoma 7, 2344–2350(2006).
   Google Scholar
• Mey UJM , MaierA, Schmidt-WolfIGHet al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support. Care Cancer 15, 877–884(2007).
   PubMed Web of Science ®Google Scholar
• Rodon P , LinassierC, GauvainJBet al. Multiple myeloma in elderly patients. presenting features and outcome. Eur. J. Hematol. 66, 11–17(2001).
   PubMed Web of Science ®Google Scholar
• Musto P , D‘AuriaF, PietrantuonoGet al. First-line treatment of multiple myeloma in elderly patients. The GINEMA (Gruppo Italiano Malattie Ematologiche dell‘Adulto) Multiple Myeloma Working Party perspective. Curr. Drug Targets 10, 906–922(2009).
   PubMed Web of Science ®Google Scholar
• Wijermans P , SchaafsmaM, TermorshuizenFet al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON study. J. Clin. Oncol. 28, 3260–3166(2010).
   Web of Science ®Google Scholar
• Offidani M , LeoniP, CorvattaLet al. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. Eur. J. Haematol. 84, 474–483(2010).
   PubMed Web of Science ®Google Scholar
• Mele G , GiannottaA, PinnaSet al. Frail elderly patients with relapsed–refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide. Leuk. Lymphoma 51, 937–940(2010).
   PubMed Web of Science ®Google Scholar
• Gozzetti A , FabbriA, OlivaSet al. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 10, 68–72(2010).
   PubMed Web of Science ®Google Scholar
• Dombret H , ChastangC, FenauxPet al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N. Engl. J. Med. 332, 1678–1683(1995).
   PubMed Web of Science ®Google Scholar
• Maslak PG , WeissMA, BermanEet al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia 10, 32–39(1996).
   PubMed Web of Science ®Google Scholar
• Stone RM , BergDT, GeorgeSLet al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N. Engl. J. Med. 332, 1671–1677(2010).
   Google Scholar
• Rowe JM , AndersenJW, MazzaJJet al. A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with accute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86, 457–462(1995).
   PubMed Web of Science ®Google Scholar
• Löwenberg B , SuciuS, ArchimbaudEet al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a Phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hematology-Oncology Cooperative Group (HOVON). Blood 90, 2952–2961(1997).
   PubMed Web of Science ®Google Scholar
• Witz F , SadounA, PerrinMCet al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 91, 2722–2730(1998).
   PubMed Web of Science ®Google Scholar
• Woronoff-Lemsi MC , WitzF, ArveuxPet al. [Intérêt thérapeutique et économique du GM-CSF dans le traitement des leucémies aiguës myéloblastiques du sujet âgé: protocole GOELAM Sa3] [Article in French]. Thérapie 56, 131–133(2001).
   PubMedGoogle Scholar
• Ritchie EK , RobozGJ. Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Curr. Hematol. Malig. Rep.5, 95–100(2010).
   PubMed Web of Science ®Google Scholar
• Pagel JM , GooleyTA, RajendranJet al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 114, 5444–5453(2009).
   PubMed Web of Science ®Google Scholar
• Suzushima H , WadaN, Yamasaki et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. Leuk. Res.34, 610–614(2010).
   PubMed Web of Science ®Google Scholar
• Dombret H , RaffouxE, GardinC. New insights in the management of elderly patients with acute myeloid leukemia. Curr. Opin. Oncol.21, 589–593(2009).
   PubMed Web of Science ®Google Scholar
• Ria NR , MoschettaM, RealeAet al. Managing myelodysplastic symptoms in elderly patients. Clin. Interv. Aging 4, 413–423(2009).
   PubMed Web of Science ®Google Scholar
• Pomeroy C , OkenMM, RydellRE, FiliceGA. Infection in the myelodysplastic syndromes. Am. J. Med.90, 338–344(1991).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN practice guidelines for the myelodysplastic syndromes. Oncology12, 53–80(1998).
   PubMed Web of Science ®Google Scholar
• Walsh TJ , AnaissieEJ, DenningDWet al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327–360(2008).
   PubMed Web of Science ®Google Scholar
• Robak T . Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging21, 779–791(2004).
   PubMed Web of Science ®Google Scholar
• Morrison VA . Infectious complications of chronic lymphocytic leukemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract. Res. Clin. Haematol.23, 145–153(2010).
   PubMed Web of Science ®Google Scholar
• Goede V , HallekM. Optimal pharmacotherapeutic management of chronic lymphocytic leukemia. Considerations in the elderly. Drugs Aging28, 163–176(2011).
   PubMed Web of Science ®Google Scholar
• Casac S , LemerySJ, ShenYLet al. US Food and Drug Administration Approval. Rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist 16, 97–104(2011).
   PubMed Web of Science ®Google Scholar
• Flinn IW , NeubergDS, GreverMRet al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia. US Intergroup Trial E2997. J. Clin. Oncol. 25, 793–798(2007).
   PubMed Web of Science ®Google Scholar
• O‘Brien S , KeatingMJ, MocarskiES. Updated guidelines on the management of cytomegalovirus reactivation inpatients with chronic lymphocytic leukemia treated with alemtuzumab. Clin. Lymphoma Myeloma7, 125–130(2006).
   PubMedGoogle Scholar
• Terrosi C , Di Genova G, Martorelli B et al. Short report. Humoral immunity to respiratory syncytial virus in young and elderly adults. Epidemiol. Infect.137, 1684–1686(2009).
   PubMed Web of Science ®Google Scholar
• Michel JP . Updated vaccine guidelines for aging and aged citizens of Europe. Expert Rev. Vaccines9, 7–10(2010).
   PubMed Web of Science ®Google Scholar
• Klastersky J , MommenP, CantraineFet al. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur. J. Cancer Clin. Oncol. 22, 807–813(1986).
   PubMedGoogle Scholar
• Bron D . Bone marrow transplantation. In: Supportive Care in Cancer. Klastersky J, Schimpff SC, Senn HJ (Eds). Marcel Dekker, Inc., New York, NY, USA, 191–212(1999).
   Google Scholar
• Fishman JA , GonzalezRG, BrandaJA. Case records of the Massachussetts General Hospital: a 45-year old man with changes in mental status after liver transplantation. N. Engl. J. Med.358, 1604–1613(2008).
   PubMed Web of Science ®Google Scholar
• Klastersky J , AounM. Infection in the immunodeficient patient. In: Clinical Infectious Diseases: Clinical Approaches. Stamm W, Waldvogel F, Carey L (Eds). Oxford University Press, Oxford, UK, 809–819(1999).
   Google Scholar
• Pickering LK , BakerCJ, FreedGLet al. Immunization programs for infants, children, adolescents and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 49, 817–840(2009).
   PubMed Web of Science ®Google Scholar
• Yahav D , Gafter-GviliA, MuchtarEet al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur. J. Cancer 45, 3131–3148(2009).
   PubMed Web of Science ®Google Scholar
• Maertens JA , FrereP, Lass-FlorlC, HeinzW, CornelyOA. Primary antifungal prophylaxis in leukemia patients. Eur. J. Cancer Suppl.5, 43–48(2007).
   Google Scholar

Website

• Surveillance, Epidemiology and End Results (SEER) database. http://seer.cancer.gov/statistics/ (Accessed 15July2011)
   Google Scholar